While the molecular traits that can be targeted with FDA-approved targeted agents for lung cancer are found in only a few per-cent of lung cancer patients, alterations of the MET gene (mutations or amplification) have been found in about 30% of lung cancers. The MET gene encodes a receptor found on the cell surface that binds a growth factor called hepatocyte growth factor.